Tomoko Yamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomoko Yamaguchi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ei Kinai
Department of Laboratory Medicine Tokyo Medical University Tokyo Japan
2 shared publications - Kagehiro Amano
Department of Laboratory Medicine Tokyo Medical University Tokyo Japan
2 shared publications - Masato Bingo
Tokyo Med Univ Hosp, Lab Med, Tokyo, Japan
2 shared publications Ryui Miyashita
2 shared publications- Yushi Chikasawa
Department of Laboratory Medicine Tokyo Medical University Tokyo Japan
2 shared publications Akiko Ioka
Medical Affairs Division Chugai Pharmaceutical Co., Ltd Tokyo Japan
1 shared publication
Latest Publications
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- Open Access
- 13 August 2026
- Published by Wiley in Haemophilia
- Vol. 32 (6) , 1338-1349
Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment
Introduction: The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease burden. Aim: This narrative review explores the clinical relevance of non‐severe haemophilia A (focusing on moderate disease), and examines the profile of patients with, and the evidence supporting the use of prophylaxis to manage, this disease form. Methods: A PubMed search was conducted (no language/date limits), using terms including ‘hemophilia’ or ‘haemophilia’, and ‘moderate’, ‘nonsevere’ or ‘non‐severe’, with the names of prophylactic agents. Results: Some patients with moderate haemophilia A experience significant disease burden (in terms of bleeding frequency and joint damage), diminished health‐related quality of life and marked economic impact. In addition, variation in bleeding phenotype across disease severity levels has been recognised, such that patients with moderate disease may have a severe phenotype and experience more frequent spontaneous bleeds than those with a mild phenotype. Few studies have specifically assessed outcomes associated with prophylaxis in patients with moderate haemophilia A. However, available data suggest that prophylaxis with FVIII concentrates and non‐factor treatments (i.e. emicizumab) provides beneficial effects in terms of bleeding frequency and joint health. Conclusion: Severity classification alone is insufficient to predict bleeding tendency, and joint bleeding and joint injury are observed in patients with moderate disease. As such, routine prophylaxis may be recommended for some patients with moderate haemophilia A.
- 13 August 2026
- Published by Wiley in Haemophilia
- Vol. 32 (6) , 1338-1349
Open AccessCurrent State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment
Introduction: The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease burden. Aim: This narrative review explores the clinical relevance of non‐severe haemophilia A (focusing on moderate disease), and examines the profile of patients with, and the evidence supporting the use of prophylaxis to manage, this disease form. Methods: A PubMed search was conducted (no language/date limits), using terms including ‘hemophilia’ or ‘haemophilia’, and ‘moderate’, ‘nonsevere’ or ‘non‐severe’, with the names of prophylactic agents. Results: Some patients with moderate haemophilia A experience significant disease burden (in terms of bleeding frequency and joint damage), diminished health‐related quality of life and marked economic impact. In addition, variation in bleeding phenotype across disease severity levels has been recognised, such that patients with moderate disease may have a severe phenotype and experience more frequent spontaneous bleeds than those with a mild phenotype. Few studies have specifically assessed outcomes associated with prophylaxis in patients with moderate haemophilia A. However, available data suggest that prophylaxis with FVIII concentrates and non‐factor treatments (i.e. emicizumab) provides beneficial effects in terms of bleeding frequency and joint health. Conclusion: Severity classification alone is insufficient to predict bleeding tendency, and joint bleeding and joint injury are observed in patients with moderate disease. As such, routine prophylaxis may be recommended for some patients with moderate haemophilia A.
- Open Access
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Comparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Open AccessComparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database